Strong through menopause: why muscle matters, especially if you're on a GLP-1

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published November 11, 2026 · Updated November 11, 2026

Weight on the scale is only one measure of midlife health. Muscle and strength support daily movement and independence as body composition shifts. That matters even more if you are considering, or already taking, a GLP-1-type medicine for weight, because these drugs can reduce lean tissue along with fat.

A randomized trial published November 9, 2026, in Nature Medicine tested whether adding regular lifting to tirzepatide—a dual GIP/GLP-1 medicine used for obesity—could protect lean tissue and strength. Weight loss was similar with or without training. Lean-tissue loss was smaller, and strength rose, in the group that lifted three times a week. Those results are encouraging, and they come with important limits, which we spell out below.

The figures below come from the paper itself, not from news summaries.

What the trial found

The T-REx study enrolled 120 adults aged 50 to 70 (mean age 57.7 years; range 50.1 to 70.3) who had obesity, or overweight plus at least one weight-related condition. Sixty were men and 60 were postmenopausal women, so half the group was postmenopausal by design. No participant had diabetes or known cardiovascular disease, and people were initially sedentary. All received tirzepatide for 40 weeks, with dose increases aimed at 15 mg weekly if tolerated. They were randomized to usual activities (61 people) or to three supervised, 1-hour, center-based resistance-training sessions each week (59 people), led by accredited exercise physiologists, with the load increased over five 8-week blocks. Everyone was asked to maintain hydration, protein intake, and fiber intake (fruit and vegetables). There was no separate diet program, and a later food-diary subset did not find a meaningful protein difference between groups. Adherence to the lifting sessions was 91%. 111 people (93%) completed the trial.

Weight and fat loss were similar. After 40 weeks, mean weight change was −22.61 kg without lifting and −22.28 kg with lifting (P = 0.694). Mean fat-mass change was −17.19 kg and −17.98 kg, respectively (P = 0.700).

Lean soft tissue declined in both groups, but less with lifting. Lean soft tissue is what a DXA scan estimates after subtracting fat and bone; it includes skeletal muscle but is not the same as muscle alone. Mean total lean-soft-tissue loss was −4.67 kg without lifting and −3.57 kg with lifting (P < 0.001). The authors reported a between-group difference of 1.09 kg (97.5% confidence interval, 0.43 to 1.75 kg). Appendicular lean soft tissue—the lean tissue in the arms and legs—also declined less with training (−2.92 kg versus −3.55 kg).

Strength fell without lifting and rose with it. Mean changes without training were −4.09 kg on the bench press, −4.42 kg on the lat pulldown, and −4.42 kg on knee extension (about 8.4%, 6.5%, and 9.0% below baseline). With training, those lifts increased by 4.68 kg, 8.58 kg, and 5.88 kg (about 10.7%, 15.7%, and 17.5%). All of those between-group comparisons had P < 0.001.

The trial was investigator-led. Eli Lilly, which makes tirzepatide, reviewed the trial protocol, provided tirzepatide through an investigator-initiated program, and reviewed a draft of the manuscript for intellectual-property and new-safety issues, with no changes made to its content; the paper says Lilly provided no other funding and had no role in the conduct of the trial. Several authors report receiving speaker honoraria from Eli Lilly. Naming tirzepatide here does not mean Kindr Health prescribes it. Compounded GLP-1 products are not FDA-approved medicines. FDA's labeling action applies to FDA-approved GLP-1 RA medicines.

What the trial cannot tell us

These are real limits, not fine print.

• Surrogate outcomes. The study measured DXA lean soft tissue and gym strength tests. It did not report falls, fractures, disability, or long-term function. The authors say more research is needed to know how a roughly 1 kg difference in lean soft tissue changes those outcomes.
• 40 weeks. We do not know what happens after the program ends, or if the medicine is stopped.
• Supervised, gym-based training. Sessions were in a dedicated gym, in groups, and closely coached. The authors note that feasibility in routine clinical practice still needs to be established. A self-directed home routine may not produce the same results.
• Who was studied. Participants were 50 to 70, without diabetes or known heart disease, not on blood-pressure medicines or statins, and new to incretin medicines. Half were men, and all of the women were postmenopausal; women in perimenopause were not included. Findings may not apply to everyone taking a GLP-1 or dual GIP/GLP-1 medicine.
• Unblinded exercise. People knew whether they were in the lifting group. DXA analysis was blinded.

Lifting did not add a detectable extra benefit on blood pressure, blood sugar, or most lipid measures beyond what tirzepatide already produced. Gastrointestinal side effects such as nausea were common in both groups.

Why muscle matters in midlife

The authors place their results in a midlife context. They cite estimates that skeletal muscle mass declines by about 0.5% to 1% per year from middle to older age, and that after age 50, muscle strength declines by about 12% to 15% per decade. They also note that loss of muscle is associated with poorer health outcomes, including higher risks of falls and fractures, in middle-aged and older adults. Those figures come from earlier research the paper cites; this trial did not itself measure aging over decades, and it did not study hormone therapy as a muscle treatment.

In a long-running U.S. study that followed women through midlife (SWAN), the rate of fat gain doubled and lean mass began to decline at the start of the menopause transition, continuing until about two years after the final period. That is one reason resistance training belongs in midlife conversations about weight and function, whether or not someone uses a GLP-1-type medicine. ACOG's October 2026 guidance on menopause symptoms centers shared decision-making about treatment, including hormone therapy when it is appropriate, based on symptoms, age, history, and goals. Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus. This trial does not change that counseling, and it is not evidence that hormone therapy preserves muscle.

A practical starter plan

This is general educational guidance, not a workout prescription and not a Kindr training program. A licensed clinician can help individualize a plan, especially if you are on a GLP-1 or dual GIP/GLP-1 medicine, are new to lifting, or have other conditions.

1. Work your major muscle groups regularly. U.S. Physical Activity Guidelines say adults need muscle-strengthening activity at least 2 days each week; the trial used three supervised sessions a week. Sessions do not have to be one-hour gym workouts from day one. What matters is regularly working major muscle groups—for example, movements similar to squats or sit-to-stands, a pushing motion, a pulling motion, and a hip hinge—using body weight, bands, cables, machines, or free weights, as appropriate and as you can do with good form.
2. Progress the load. In the study, the first weeks emphasized technique and lighter to moderate effort, then intensity increased. A simple rule is to add a little resistance, a few repetitions, or a slightly harder variation when a session starts to feel easy, rather than jumping straight to heavy loads.
3. Keep protein in the picture, but do not guess a dose from this trial. Everyone in the study was asked to maintain protein intake; the investigators did not test a specific gram target, and protein intake did not differ meaningfully between groups in the food-diary subset. A practical starting point is to include a protein source at meals. If appetite is lower on a GLP-1-type medicine, a clinician or registered dietitian can help you set an amount that fits your health history.
4. Check in with a clinician, then start where you are. Supervised training in the trial is not the same as exercising alone at home. If you have joint pain, balance problems, heart or blood-pressure issues, or you are starting a new medicine, talk with a clinician before you change your routine. A qualified trainer or exercise professional can help with form if that is available to you.

The goal is function—not just a lower number on the scale.

If you take a GLP-1: a safety note

On November 9, 2026—the same day this trial was published—FDA announced that it is requiring safety labeling changes for all FDA-approved glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines, a class that includes tirzepatide products, whether they are used for type 2 diabetes, weight management, or another approved use, because of a potential increased risk of a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). This is a labeling update about a potential risk—not a finding that these medicines are proven to cause NAION, and not a claim that NAION is common.

NAION can cause sudden, painless vision loss in one eye, including permanent vision loss. Contact a clinician right away if your vision changes suddenly. FDA's patient guidance does not tell people to stop their GLP-1 medicine on their own. We cover the details, including how rare FDA says the events were in trial data, in our journal post on FDA's GLP-1 NAION labeling.

This article likewise does not advise you to start, stop, or change any medicine. Decisions about a GLP-1, hormone therapy, or an exercise plan belong with you and a licensed clinician.

Where Kindr fits

At Kindr Health, menopause and midlife care is clinician-led. The conversation can include symptoms, weight, and how to protect strength—without treating a trial or a headline as a one-size-fits-all plan. Kindr Health is a telehealth platform that connects patients with licensed clinicians; we do not run an in-house gym or a branded training program. Kindr's board-certified clinicians can talk through what may fit you — Kindr Care patient intake is open now. Start your intake at kindr.health.

This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping, or changing any medication or exercise routine. See our medical disclaimer.

Medically reviewed by Kindr Health Clinical Team
Last updated: November 11, 2026